clinical trial · NCT06555328
Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa
Chronic Urticaria, IdiopathicHidradenitisHidradenitis SuppurativaCSU lower dose treatmentCSU high dose treatmentCSU non responders IgE - high dose treatmentHS low dose treatmentHS medium dose treatmentHS high dose treatment
brief summary
The study duration for an individual subject includes screening (14 days), the treatment period (28 days) and the observational follow-up period of 28 days, in total 70 days ± 6 days. All subjects will receive IMP for 28 days followed by one End of Study (EOS) visit, 4 weeks after EOT visit.
started
Jan 2, 2025
primary completion
Jan 22, 2026
completion
Jan 22, 2026
last updated
Feb 3, 2026
official title
Phase 2a Open-Label Basket Study to Evaluate Safety and Pharmacokinetics of INF904, an Oral C5aR1 Inhibitor, in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol